 |
|
|
| |
Similar Cognition Outcomes After 48 Weeks for Tenofovir (TDF)/Emtricitabine (FTC) + Atazanavir/Ritonavir (ATV/r)-Experienced HIV+ Patients or Those Simplifying to Abacavir (ABC)/Lamivudine (3TC) + ATV
|
| |
| |
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO
K Robertson,1 P Maruff,2 D Wohl,3 L Bhatti,4 CB Small,5 H Edelstein,6 HH Zhao,7 DA Margolis,7 LL Ross,8 MS Shaefer8 1AIDS Neurological Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2Cogstate Ltd, Melbourne, Australia; 3AIDS Clinical Trials Unit, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 4AIDS Healthcare Foundation, Beverly Hills, CA, USA; 5New York Medical College, Valhalla, NY, USA; 6Alameda County Medical Center, Oakland, CA, USA; 7GlaxoSmithKline, Research Triangle Park, NC, USA; 8ViiV Healthcare, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
